Vaxxinity, Inc. (VAXX)

OTCMKTS · Delayed Price · Currency is USD
0.0100
0.00 (0.00%)
Mar 6, 2026, 4:00 PM EST
4,900%
Market Cap 1.27M
Revenue (ttm) n/a
Net Income (ttm) -56.93M
Shares Out 126.75M
EPS (ttm) -0.45
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 257
Average Volume 2,983
Open 0.0200
Previous Close 0.0100
Day's Range 0.0100 - 0.0200
52-Week Range 0.0000 - 0.0500
Beta 3.78
RSI 59.10
Earnings Date n/a

About Vaxxinity

Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology, cardiovascular diseases, and coronaviruses in the United States. Its product pipeline comprises UB-311, which is in phase 2 clinical trial that targets toxic forms of aggregated amyloid-b in the brain to fight alzheimer’s disease; UB-312, which is in phase 1 clinical trial that targets toxic forms of aggregated α-synuclein in the brain to fight parkinson’s disease and other synucleinopathies, such as Lewy body dementia an... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2021
Employees 65
Stock Exchange OTCMKTS
Ticker Symbol VAXX
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.